ORPHA:163596
Hemoglobin Bart's fetalis syndrome
Also known as: HBHF · Haemoglobin Bart's disease · Haemoglobin Bart's hydrops fetalis · Hb Bart's hydrops fetalis syndrome · Hemoglobin Bart's disease · Hemoglobin Bart's hydrops fetalis · Homozygous alpha0-thalassemia · Alpha-thalassemia hydrops fetalis · Alpha-thalassemia major · BHFS
Publications
318
64.3th percentile
Trials
1
Interventional, condition-specific
Researchers
897
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A severe form of alpha-thalassemia that is mostly lethal, and associated with severe long-term outcome and lifelong transfusions in survivors. It is characterized by fetal onset of generalized edema, pleural and pericardial effusions, and severe hypochromic anemia.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015579
- UMLS:C0272005
Additional Mondo synonyms (5)
HBA1;HBA2 digenic quadallelic Hb Bart’s hydrops fetalis · Hb Bart’s hydrops fetalis caused by quadallelic variation in HBA1;HBA2 · Hb Bart’s hydrops fetalis related to quadallelic variation in HBA1 and HBA2 · alpha-thalassemia hydrops fetalis · homozygous alpha0-thalassemia
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
318 matched papers (159 in last 10 years) Source
- Phenotype characterisedPresent
11 HPO annotations (e.g. Pallor; Polyhydramnios; Oligohydramnios) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
1 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
11
Associated phenotypes · MONDO:0015579
- Pallor
- Polyhydramnios
- Oligohydramnios
- Congestive heart failure
- Pericarditis
Showing 5 of 11 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
318
318 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
318 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
159 in the last 10 years · medium confidence · 64.3th percentile (publications denominator)
Phrase hits: 318 · MeSH hits: 0
Who's working on it?
897
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Tongsong T35 papers · 2026
Department of Obstetrics and Gynecology, Faculty of Medicine Chiang Mai University, Chiang Mai 50200, Thailand. ttongson@mail.med.cmu.ac.th.
Papers in Europe PMC - 02Luewan S30 papers · 2026
Department of Obstetrics and Gynecology, Faculty of Medicine, Chiangmai University, Chiangmai, Thailand.
Papers in Europe PMC - 03Srisupundit K21 papers · 2026
Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Papers in Europe PMC - 04Tongprasert F19 papers · 2026
Maternal Fetal Medicine Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. fpunyath@med.cmu.ac.th
Papers in Europe PMC - 05Fucharoen S13 papers · 2025
3Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakorn Pathom, 73170 Thailand.
Papers in Europe PMC - 06Jatavan P12 papers · 2026
Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Papers in Europe PMC - 07Sirichotiyakul S9 papers · 2026
Department of Obstetrics and Gynecology, Faculty of Medicine Chiang Mai University, Thailand.
Papers in Europe PMC - 08Li DZ8 papers · 2021
Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center Affiliated to Guangzhou Medical University, Guangzhou, Guangdong, China.
Papers in Europe PMC - 09Wanapirak C8 papers · 2026
Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Papers in Europe PMC - 10Amid A6 papers · 2025
Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; none in our sample are currently recruiting.
Data as of 11 September 2026
1 interventional trial — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 80.1th percentile).
medium confidence · 80.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT04872179·RECRUITING·International Registry of Patients With Alpha Thalassemia
Not reviewed·Conditions: Alpha-Thalassemia · Alpha Thalassemia Major · Alpha Thalassemia Minor·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 6 · after dedupe 6 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 6 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (6)
- isrctn·ISRCTN89652137·No longer recruiting·Holistic approach to investigate dental caries in diabetes patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15028850·No longer recruiting·A randomised phase II trial of selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma (RRMM) patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN53348826·No longer recruiting·Renal Adjuvant Multiple Arm Randomised Trial (RAMPART)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10639376·No longer recruiting·A trial looking at whether stereotactic radiotherapy together with chemotherapy is a useful treatment for people with locally advanced bile duct cancer (ABC-07)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16783472·No longer recruiting·Assessing the safety and tolerability of oral ruxolitinib in combination with 5-azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN66118656·No longer recruiting·Cell SALVage in Obstetrics
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Hemoglobin Bart's fetalis syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Hemoglobin Bart's fetalis syndrome" OR "Haemoglobin Bart's disease" OR "Haemoglobin Bart's hydrops fetalis" OR "Hb Bart's hydrops fetalis syndrome" OR "Hemoglobin Bart's disease" OR "Hemoglobin Bart's hydrops fetalis" OR "Homozygous alpha0-thalassemia" OR "Alpha-thalassemia hydrops fetalis" OR "Alpha-thalassemia major" OR "HBA1;HBA2 digenic quadallelic Hb Bart’s hydrops fetalis" OR "Hb Bart’s hydrops fetalis caused by quadallelic variation in HBA1;HBA2" OR "Hb Bart’s hydrops fetalis related to quadallelic variation in HBA1 and HBA2"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hemoglobin Bart's fetalis syndrome" OR "Haemoglobin Bart's disease" OR "Haemoglobin Bart's hydrops fetalis" OR "Hb Bart's hydrops fetalis syndrome" OR "Hemoglobin Bart's disease" OR "Hemoglobin Bart's hydrops fetalis" OR "Homozygous alpha0-thalassemia" OR "Alpha-thalassemia hydrops fetalis" OR "Alpha-thalassemia major" OR "HBA1;HBA2 digenic quadallelic Hb Bart’s hydrops fetalis" OR "Hb Bart’s hydrops fetalis caused by quadallelic variation in HBA1;HBA2" OR "Hb Bart’s hydrops fetalis related to quadallelic variation in HBA1 and HBA2"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: HBHF; BHFS
Confidence reasoning
- Preferred label is multi-word and distinctive
- 2 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T08:09:15.385Z
